UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint

Journal of pharmacokinetics and pharmacodynamics, 2022-06, Vol.49 (3), p.283-291

2022

Volltextzugriff (PDF)

Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals

Journal of pharmacokinetics and pharmacodynamics, 2022-10, Vol.49 (5), p.487-491

Hu, Chuanpu

2022

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients

Journal of clinical pharmacology, 2022-02, Vol.62 (2), p.182-189

2022

Volltextzugriff (PDF)

Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis

Journal of pharmacokinetics and pharmacodynamics, 2016-02, Vol.43 (1), p.45-54

2016

Volltextzugriff (PDF)

Variability of Target-controlled infusion is less than the variability after bolus injection

Anesthesiology (Philadelphia), 2005-03, Vol.102 (3), p.639-645

2005

Volltextzugriff (PDF)

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis

Journal of pharmacokinetics and pharmacodynamics, 2023-04, Vol.50 (2), p.133-144

2023

Volltextzugriff (PDF)

A joint model for nonlinear longitudinal data with informative dropout

Journal of pharmacokinetics and pharmacodynamics, 2003-02, Vol.30 (1), p.83-103

2003

Volltextzugriff (PDF)

Landmark and longitudinal exposure–response analyses in drug development

Journal of pharmacokinetics and pharmacodynamics, 2017-10, Vol.44 (5), p.503-507

2017

Volltextzugriff (PDF)

Erratum to: Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis

Journal of pharmacokinetics and pharmacodynamics, 2016-02, Vol.43 (1), p.55-55

2016

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

Journal of clinical pharmacology, 2020-07, Vol.60 (7), p.889-902

2020

Volltextzugriff (PDF)

Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

Clinical pharmacology and therapeutics, 2021-01, Vol.109 (1), p.131-139

2021

Volltextzugriff (PDF)

No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost

Clinical pharmacology and therapeutics, 2024-01, Vol.115 (1), p.25-28

2024

Volltextzugriff (PDF)

Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients

Journal of pharmacokinetics and pharmacodynamics, 2017-10, Vol.44 (5), p.437-448

2017

Volltextzugriff (PDF)

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

Journal of clinical pharmacology, 2015-02, Vol.55 (2), p.221-229

2015

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

Journal of clinical pharmacology, 2018-05, Vol.58 (5), p.613-627

2018

Volltextzugriff (PDF)

Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin‐6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

Journal of clinical pharmacology, 2018-07, Vol.58 (7), p.939-951

2018

Volltextzugriff (PDF)

Population pharmacokinetics : A regulatory perspective

Clinical pharmacokinetics, 1999-07, Vol.37 (1), p.41-58

1999

Volltextzugriff (PDF)

Exposure‐Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

Journal of clinical pharmacology, 2018-11, Vol.58 (11), p.1501-1515

2018

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

Journal of clinical pharmacology, 2019-04, Vol.59 (4), p.590-604

2019

Volltextzugriff (PDF)

Joint longitudinal model development: application to exposure–response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab

Journal of pharmacokinetics and pharmacodynamics, 2018-10, Vol.45 (5), p.679-691

2018

Volltextzugriff (PDF)

An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

Journal of clinical pharmacology, 2008-07, Vol.48 (7), p.812-822

2008

Volltextzugriff (PDF)

Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure–response modeling of Mayo scores for golimumab in patients with ulcerative colitis

Journal of pharmacokinetics and pharmacodynamics, 2018-12, Vol.45 (6), p.803-816

2018

Volltextzugriff (PDF)

Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis

Journal of pharmacokinetics and pharmacodynamics, 2014-06, Vol.41 (3), p.239-250

2014

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

Journal of clinical pharmacology, 2009-02, Vol.49 (2), p.162-175

2009

Volltextzugriff (PDF)

A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

Journal of pharmacokinetics and pharmacodynamics, 2018-08, Vol.45 (4), p.523-535

2018

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Aktive Filter

KollektionLWW Total

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(37)
Pharmacology & Pharmacy
(37)
Science & Technology
(37)
Humans
(29)
Models, Biological
(19)
Biochemistry
(17)
Biomedical And Life Sciences
(17)
Biomedical Engineering And Bioengineering
(17)
Biomedicine
(17)
Pharmacology/toxicology
(17)
Pharmacy
(17)
Veterinary Medicine/veterinary Science
(17)
Nonmem
(16)
Pharmacokinetics
(14)
Monoclonal Antibodies
(13)
Population Pharmacokinetic/pharmacodynamic Modeling
(13)
Original Paper
(11)
Body Weight
(9)
Dose-Response Relationship, Drug
(9)
Psoriasis - Drug Therapy
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint

Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals

Pharmacokinetic/Pharmacodynamic Analysis of Guselkumab for Treatment of Palmoplantar Pustulosis: Clinical Implications of Guselkumab Dose, Disease Severity, and Smoking in Japanese Patients

Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis

Variability of Target-controlled infusion is less than the variability after bolus injection

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis

A joint model for nonlinear longitudinal data with informative dropout

Landmark and longitudinal exposure–response analyses in drug development

Erratum to: Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis

Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis

Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis

No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and Cost

Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients

Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis

Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin‐6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

Population pharmacokinetics : A regulatory perspective

Exposure‐Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis

Joint longitudinal model development: application to exposure–response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab

An Improved Approach for Confirmatory Phase III Population Pharmacokinetic Analysis

Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure–response modeling of Mayo scores for golimumab in patients with ulcerative colitis

Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

Aktive Filter

Suchergebnisse filtern